Immix Biopharma Posts $35.6M Nine-Month Loss, Holds $336.3M Cash After $117.2M Raise
IMMX has more than doubled off its 52-week low of $3.26.
Summary
Immix Biopharma reported a $35.6 million net loss for the first nine months of 2026 as G&A and R&D spending rose sharply, and ended September with $336.3 million in cash and short-term investments after its $117.2 million September offering. Management says that funds at least 12 months of operations.
Key Events · Earnings and Guidance · IMMX
-
Nine-Month Net Loss Widens to $35.6M
Net loss for the nine months ended September 30, 2026 was $35,570,869 versus $18,750,783 a year earlier, pushing the accumulated deficit to $140,034,153.
-
Cash Reaches $336.3M After Offering
Cash, cash equivalents and short-term investments totaled approximately $336.3 million at September 30, 2026, plus $4.6 million in long-term U.S. Treasury investments, following the $117.2 million net proceeds from the September 2026 offering at $11.00 per share.
-
Operating Spend Steps Up Sharply
General and administrative expense rose to $22,350,139 for the nine months from $8,531,476, and research and development to $16,855,930 from $10,531,663, driven by hiring, equity awards and capital-raise related professional fees.
-
Cash Burn of $33.9M Over Nine Months
Net cash used in operating activities was $33,870,537 for the nine months ended September 30, 2026, versus $12,900,697 a year earlier.
Analysis · IMMX · Life Sciences
Spending is ramping hard. General and administrative expense more than doubled to $22.4 million for the nine months, and research and development rose to $16.9 million, driving a $35.6 million net loss versus $18.8 million a year earlier. Against that, the September 2026 offering at $11.00 per share added $117.2 million net, lifting cash, cash equivalents and short-term investments to $336.3 million plus $4.6 million in long-term Treasuries — enough, management says, to fund operations for at least the next 12 months. The key question for holders is how fast that burn accelerates as the company moves NXC-201 toward a planned randomized Phase 3 in newly diagnosed AL amyloidosis; at the current nine-month cash burn of $33.9 million, the balance sheet buys years of runway, not quarters.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMMX was trading at $8.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $669M. The 52-week trading range was $3.26 to $15.10. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.